Zydus Pharmaceuticals (USA) Inc,. has come a long way since its first commercial launch in August 2005.
HISTORY OF ZYDUS
Since its first commercial launch in 2005, Zydus Pharmaceuticals (USA) Inc. has been providing quality, affordable generic drugs to the US market. Exceptional service to both customers and patients who rely on its products has been a key driver for the company’s success. Zydus Pharmaceuticals currently offers over 495 SKUs and is ranked the fifth largest unbranded generic corporation in the US based on dispensed prescriptions (IQVIA, National Prescription Audit, MAT May 2022). With a mission of growth, Zydus Pharmaceuticals is focused on expanding its portfolio of complex generics, including modified release solid orals, transdermals, injectables, and oral suspensions. To date, the company has filed 129 drug master files (DMFs), has received final USFDA approval on 288 abbreviated new drug applications (ANDAs), and has over 120 ANDAs pending approval with the USFDA. The company also has approximately 300 additional products in various stages of development.
2022 AT A GLANCE
2022 has been an exciting time for Zydus Pharmaceuticals (USA) Inc. as we rebrand our identity along side our parent company, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited). Our new logo represents our key corporate ideals and focus. Two hearts come together to enclose ‘us’ at the core to represent the company’s inclusiveness. The teal and purple colors represent the Zydus’ commitment to science and the company’s dedication to care and nurturance.
Our philosophies surrounding care and nurturance are at the heart of Zydus Pharmaceuticals’ core. We remain diligent in ensuring a quality and affordable supply of our products in the US to provide continuity for the patients who use our medications. Zydus Pharmaceuticals successfully launched nine products in the first half the year, including its first ophthalmic product. Three of the company’s launches to date have come from its injectables division, which has seen tremendous growth over the past several years. As Zydus Pharmaceuticals enters the second half of the year, it plans to bring more cost-saving generics to market to help improve patients’ lives.
ZYDUS LIFESCIENCES LIMITED
Zydus Lifesciences is a fully integrated, global healthcare provider looking to make a meaningful difference in serving patients and communities. With a legacy of over 70 years, the company is driven by care, compassion, and commitment to innovation. Zydus Lifesciences is headquartered in Ahmedabad, India and is India’s fourth largest pharmaceutical company. The company has business operations in 55 countries including, the US, India, France, Spain, Brazil, Mexico, and South Africa. From new chemical entities to vaccines, biosimilars, novel biologics, and niche technologies, Zydus is exploring different ideas to develop differentiated medicines for the future. Zydus Lifescience’s ZyCoV-D vaccine was the world’s first plasmid DNA vaccine to be approved for human use and is currently approved in India as a two-dose regimen for adults and children aged 12 years and above. Driven by passion for innovation, Zydus Lifesciences strives for excellence to make a difference in the world of healthcare.
For more information, visit zydususa.com.